Business Wire

MYPINPAD Achieves PCI SSC SPOC Approval for IOS Devices

7.1.2020 03:01:00 EET | Business Wire | Press release

Share

MYPINPAD (“MPP”), the global leader in secure personal authentication for payment solutions, has achieved Payment Card Industry (PCI) Security Standards Council certification for its iOS Software based PIN entry on a Commercial off-the-shelf (SPoC) solution.

The UK based fintech company is amongst the world’s first to achieve certification for its innovative PIN on Mobile solution (“MPP mPOS”), evaluated by Brightsight. The solution enables everyday smartphones and tablets to replace traditional Point of Sale terminals and PIN entry mPOS devices.

MYPINPAD’s innovative SPoC solution is seen as a major enabler for the predicted massive expansion in the number of payment acceptance devices globally. The solution is easily integrated into 3rd party applications and can be delivered ‘As-a-Service’.

The cost of hardware-based PIN pads is seen as a significant barrier to global card acceptance adoption. MPP mPOS will enable even the smallest of enterprises and those in under-served economies to accept card payments, while also relieving merchants and larger retailers from the burden of purchasing and maintaining large estates of traditional POS terminals.

Importantly, PIN entry is via a standard PIN pad image (not scrambled), ensuring seamless customer adoption. The technology supports use by people with visual impairment and people with other disabilities, which is critical in certain markets, delivering the world’s first fully inclusive solution.

Phil King, CEO and Chairman, MYPINPAD, said: “MYPINPAD has been at the forefront of the thinking about and the development of PIN on Mobile since 2012. We are proud to have achieved PCI SPoC certification for IOS devices, featuring a standard non-scrambled PIN pad that consumers trust and are familiar with. We look forward to announcing the same for Android devices soon.

Since inception MYPINPAD’s commitment to this technology has been unwavering. Our platform has been designed to make available Secure Card Reader-based and contactless payment acceptance solutions, the latter called MPP SoftPOS as a software only solution, with attestation and with the pre-integration of our code inside every payShield HSM. We look forward to being able to offer on a global basis PCI SPoC certified MPP mPOS on all devices and scheme approved MPP SoftPOS on Android devices in the new year.”

"It is a pleasure to work with the creative and skilled MYPINPAD team and help bring new and innovative payment solutions to market. We look forward in continuing our partnership with MYPINPAD in the years to come." says Rob van Marrewijk, Director Business Development at Brightsight.

***ENDS***

About MYPINPAD:

MYPINPAD is a global leader in secure personal authentication for payment solutions residing on commercially available smartphones and tablets. Our proprietary and globally patented technology secures and protects the input of sensitive information on touchscreens creating a trusted environment. MYPINPAD’s innovative solution set removes the reliance on specialised hardware for personal authentication; reduces cost and complexity, promotes rapid adoption and leverages the connected capabilities of smart devices.

Please visit www.mypinpad.com to discover more about this transformational technology.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Becky Sales
becky@skyparlour.com
07803204780

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Enhertu ® Approved in the EU as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer27.10.2026 09:30:00 EET | Press release

Enhertu® (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive (immunohistochemistry [IHC] 3+ or in-situ hybridization [ISH]+) breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. In DESTINY-Breast05, Enhertu significantly reduced the risk of in

Avanzanite Bioscience Expands UK Presence and Appoints Sarah O’Connell as Country Manager27.10.2026 09:00:00 EET | Press release

Avanzanite Bioscience B.V., a European pharmaceutical company focused on rare diseases, today announced the expansion of its United Kingdom (UK) presence and the appointment of Sarah O’Connell as UK Country Manager. The move strengthens Avanzanite’s long-term commitment to the UK and its ability to help eligible patients access innovative rare disease medicines. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261027035012/en/ Sarah O'Connell, Country Manager, UK, Avanzanite Bioscience “The UK is essential to our ambition of building Avanzanite into a European rare disease champion. We feel a deep and lasting connection to this market and there is no European reach without the UK,” said Adam Plich, co-founder and CEO, Avanzanite Bioscience. “At a time when parts of the life sciences sector are reassessing their investment and presence in the UK, we are choosing to commit and build for the long term. With Sarah’s extensive rare

LTM Secures Strategic Engagement with a Global Banking and Financial Services Firm27.10.2026 06:30:00 EET | Press release

LTM, the Business Creativity partner to the world's largest enterprises, has secured a strategic engagement with a large global banking and financial services firm, further strengthening its position as a trusted technology and transformation partner to leading financial institutions. This two-year engagement is already underway with an option to extend for an additional year and has a potential value of up to USD 100 million. The engagement reflects the continued expansion of LTM’s relationship with the client and its growing role in advancing strategic technology programmes and supporting supplier consolidation initiatives across the organization. Under the agreement, LTM will serve as a preferred partner driving the consolidation and delivery of strategic technology requirements across key wealth, personal banking, and global functions. The engagement will leverage LTM’s deep banking-domain expertise, engineering excellence, and global delivery capabilities to support the client’s t

DDN Selected to Modernize Research Data Infrastructure at UNSW Sydney26.10.2026 23:30:00 EET | Press release

DDN, the global leader in AI and data intelligence solutions, today announced that UNSW Sydney has selected DDN to deliver a new research data storage environment as part of the university’s Research Data Experience (RDE) program. Working with Australian software company Arcitecta, DDN will combine its EXAScaler parallel file system with Arcitecta’s Mediaflux® data management platform to help researchers spend less time managing data and more time using it. Following an extensive 18-month evaluation, UNSW selected an integrated approach that will replace 11 legacy storage systems with a coordinated environment for high-performance storage and enterprise data management. The decision reflects a broader challenge facing research-intensive institutions: how to support rapidly expanding scientific datasets while simplifying infrastructure, improving data accessibility and managing long-term costs. Built for data-intensive research, high-performance computing and AI workloads, DDN EXAScaler

Agent Assurance by TestMu AI Is Now Generally Available, Letting Teams Test What Their AI Agents Actually Change26.10.2026 17:15:00 EET | Press release

TestMu AI (formerly LambdaTest), the world's first Agentic AI-powered Quality Engineering platform, today announced the general availability of Agent Assurance. Agent Assurance tests AI agents that take actions, such as calling tools, writing files, and changing records, by checking what a run actually changed rather than what the agent says it did. Any team can now create a TestMu AI account and run it against its own agent without booking a demo first. Agent Assurance launched on August 17, 2026, behind a waitlist and a guided onboarding session. Since then, Rook, the CLI that runs Agent Assurance, has shipped a steady run of releases, shaped by feedback from early teams. Agent evaluation has mostly graded the final reply, and that reply can be wrong about the agent's own work. In CXBench, a benchmark of LLM agents in regulated customer-experience workflows published in October 2026, 80.1% of runs that reached the right outcome still failed the process checks, and only 13.8% passed b

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye